Lung Cancer News and Research

Latest Lung Cancer News and Research

New understanding about function of MYC proteins

Scientists may have discovered why a protein called MYC can provoke a variety of cancers. Like many proteins associated with cancer, MYC helps regulate cell growth. A study carried out by researchers at the National Institutes of Health and colleagues found that, unlike many other cell growth regulators, MYC does not turn genes on or off, but instead boosts the expression of genes that are already turned on.

28 Sep 2012

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA

ARIAD Pharmaceuticals, Inc. today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational BCR-ABL inhibitor, ponatinib, to the U.S. Food and Drug Administration (FDA).

28 Sep 2012

OncoGenex commences custirsen Phase 3 trial in non-small cell lung cancer

OncoGenex Pharmaceuticals, Inc. announced today the initiation of ENSPIRIT, a Phase 3 trial evaluating custirsen for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed after initial chemotherapy treatment has failed.

28 Sep 2012

KSU creates simple blood test that can accurately detect lung and breast cancer’s early stages

Researchers at Kansas State University have developed a simple blood test that can accurately detect the beginning stages of cancer.

27 Sep 2012

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.

27 Sep 2012

CivaTech Oncology receives NIH/NCI Phase II Contract for CivaSheet device to treat NSCLC

CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.

26 Sep 2012

Pervenio Lung RS from Life Technologies

Life Technologies Corporation today announced the launch of Pervenio Lung RS. First-of-its-kind, the molecular test has been documented to reliably identify early stage lung cancer patients who are at high risk for mortality following surgery. It also fulfills an unmet need for prognostic information to guide preventative treatment and improve disease management.

25 Sep 2012

Location of fat determines diabetes risk in obesity

New tools are needed to discriminate risk for prediabetes and diabetes among obese individuals, suggest findings from a US study.

24 Sep 2012

ESMO Designated Center of Integrated Oncology and Palliative Care accreditation for 16 new centers

The European Society for Medical Oncology has awarded ESMO Designated Center of Integrated Oncology and Palliative Care accreditation to 16 new oncology centers. The centers will receive the acknowledgment at the ESMO 2012 Congress, in Vienna, Austria, 28 September - 2 October.

24 Sep 2012

Natural killer cells may influence lung cancer susceptibility

Why do many heavy smokers evade lung cancer while others who have never lit up die of the disease? The question has vexed scientists for decades.

24 Sep 2012

Exposure to near-roadway air pollution can cause or exacerbate asthma in L.A. County children

Research conducted at the University of Southern California (USC) indicates that at least 8 percent of the more than 300,000 cases of childhood asthma in Los Angeles County can be attributed to traffic-related pollution at homes within 75 meters (a little less than 250 feet) of a busy roadway.

24 Sep 2012

Secondhand smoke continues to take a grievous toll on nonsmokers

Secondhand smoke is accountable for 42,000 deaths annually to nonsmokers in the United States, including nearly 900 infants, according to a new UCSF study.

21 Sep 2012

Routine tests flag up cancer danger in cryptogenic stroke

Blood tests and imaging findings could point to hidden malignancies in patients with cryptogenic stroke, say researchers.

21 Sep 2012

Alcohol refrain for bone density gain

Abstinence from alcohol for 2 months could correct the imbalance between bone formation and resorption in alcoholic men, a study shows.

21 Sep 2012

Routine tests flag up cancer danger in cryptogenic stroke

Blood tests and imaging findings could point to hidden malignancies in patients with cryptogenic stroke, say researchers.

21 Sep 2012

MD Anderson introduces Moon Shots Program to reduce cancer deaths

The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

21 Sep 2012

Antiwasting supplements provide moderate improvements in child health

Study results show that ready-to-use supplementary food, provided to children at risk for malnutrition as part of a general food distribution program, does not significantly improve child weight.

20 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012